Start Date
September 23, 2016
Primary Completion Date
October 4, 2016
Study Completion Date
October 4, 2016
Sirukumab
This intervention will be provided in a 1.0 mL pre-filled syringe (PFS) fitted with spring-powered, disposable autoinjector device for single SC use that is permanently assembled on the syringe. The sirukumab PFS is aseptically filled to deliver a dose of 50 mg/1.0 mL of sirukumab.
Placebo
This intervention will be provided in a 1.0 mL pre-filled syringe (PFS) fitted with spring-powered, disposable autoinjector device for single SC use that is permanently assembled on the syringe. The sirukumab PFS is aseptically filled to deliver a dose of 50 mg/1.0 mL of sirukumab.
Rescue medication
Rescue medication (salbutamol/albuterol) shall be supplied to subjects at Screening for use when needed during the study.
GSK Investigational Site, Santiago de Compostela. La Coruña.
GSK Investigational Site, Girona
GSK Investigational Site, Richmond
GSK Investigational Site, Richmond
GSK Investigational Site, Alcorcón (Madrid)
GSK Investigational Site, Aventura
GSK Investigational Site, Cincinnati
GSK Investigational Site, Long Beach
Lead Sponsor
GlaxoSmithKline
INDUSTRY